

New modalities in management of resistant diabetic macular edema

Abstract

Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Application of laser photocoagulation has a limited effect. Anti-vascular endothelial growth factor (anti-VEGF) therapy has been a major breakthrough in the management of DME. Despite the improvement in DME after laser or anti VEGF therapy, persistent type remains a challenge due to different pathogenesis and biochemical pathways. This talk focuses on therapeutic options for resistant (refractory) DME, which include corticosteroids, laser, surgery and new agents.

My talk will cover these points according to the available time

Classification of DME

Risk factors

Pathogenesis

Diagnosis

Treatment (prevention & control)

Anti VEGF

Micro pulse laser

Steroid therapy (injection & implant)

Vitrectomy

New agents

Conclusion and recommendations

